I was only pointing out that high value and recognition can come before market approval. All the talk is focused on how long it will take to get through Phase 3 from where the company is now. I'm only pointing out that completion of Phase 1 will be sufficient for a major pharma deal provided Phase 1 confirms all mouse results, including efficacy, in humans.
If a pharma pays $150 million up front, and assuming more dilution to 200 million o/s, what will that do to the share price even at 10 times earnings when there is the prospect of another $150 million shortly, and the finances for a rapid advancement of other viricides targeting HIV, HEP B and C, Dengue, HPV, etc.